Assessment of Detection of Apoptosing Retinal Cells in glaucoma

Not Applicable

Completed

• Conditions: Eye Diseases; Glaucoma

• Registration Number: ISRCTN59484478
• Lead Sponsor: St Mary's Hospital NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10-24
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

Our patient group will be identified from the glaucoma clinics at The Western Eye Hospital according to the following inclusion criteria:
1. For all patient groups:
1.1. Aged 18 years or over
1.2. Clear optical media in the studied eye
1.3. Previous experience at automated perimetry
1.4. No ocular or systemic disease (other than glaucoma in the test group)
1.5. Refractive error not higher than spherical equivalent of 6 D
1.6. Best corrected visual acuity equal to 6/9 or better
2. All subjects will have to have been shown to be able to perform reliable visual field testing using the HFA 640 instrument, central 24-2 program, to yield full thresholds (Deviation, MD-HFA and Pattern Standard Deviation, PSD-HFA), and have had good fundoscopy with assessment of their optic disc
3. Subjects willing and able to make the required study visits
4. All subjects must be able to understand the information describing the study and give informed consent

Exclusion Criteria

1. History of current or severe, unstable or uncontrolled cardiovascular, hepatic or renal disease (e.g., sinus bradycardia, cardiac failure) precluding safe administration of a topical beta antagonists
2. History of bronchial asthma or chronic obstructive airways disease precluding use of a topical beta antagonist
3. Women of childbearing age will be excluded from the study unless they have been surgically sterilised
4. Contact lens wearers will not be allowed to participate in the study
5. Previous ocular surgery such as retinal detachment, multiple surgical procedures including glaucoma
6. Co-existing disease which may affect DARC count e.g., retinal vein occlusion, age-related macular degeneration (AMD)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome measure is the DARC count

Secondary Outcome Measures

Name	Time	Method
The secondary measures are the visual field and optic disc assessment